Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Theravance Biopharma R&D IP, LLC”

252 pharma patents match "Theravance Biopharma R&D IP, LLC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 252
Index total 30,257
Page 4 / 11

Quick answer

This filtered view shows 252 pharmaceutical patents matching "Theravance Biopharma R&D IP, LLC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

252 results for “Theravance Biopharma R&D IP, LLC” · 30,257 patents in full index Clear search

  1. US 10836763

    5 to 7 membered heterocyclic amides as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted
  2. US 10829438

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted
  3. US 10774080

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  4. US 10759813

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  5. US 10752599

    Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  6. US 10745405

    Glucuronide prodrugs of Janus kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  7. US 10744104

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  8. US 10745394

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  9. US 10722504

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance Biopharma R&D IP, LLC · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted
  10. US 10696656

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Theravance Biopharma R&D IP, LLC · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted
  11. US 10577347

    Crystalline forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  12. US 10576073

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Theravance Biopharma R&D IP, LLC · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  13. US 10570120

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  14. US 10570092

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  15. US 10562894

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  16. US 10550081

    Crystalline freebase forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  17. US 10548879

    (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Theravance Biopharma R&D IP, LLC · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  18. US 10550118

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  19. US 10548886

    Methods of treatment using a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  20. US 10538513

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  21. US 10526330

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  22. US 10519153

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  23. US 10493077

    Fused imidazo-piperidine JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  24. US 10494382

    Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and water

    Theravance Biopharma R&D IP, LLC · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted